Trials / Completed
CompletedNCT04733833
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19
A Randomized, Controlled Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this Phase 2 study is to test safety, efficacy, and tolerability of an oral preparation of VB-201 in patients with severe COVID-19
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VB-201 + Standard of care | Daily oral administration of VB-201- 160 mg (80 mg BID) with standard of care |
| DRUG | Standard of care | Standard of care |
Timeline
- Start date
- 2021-01-26
- Primary completion
- 2022-10-25
- Completion
- 2022-10-25
- First posted
- 2021-02-02
- Last updated
- 2023-02-01
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT04733833. Inclusion in this directory is not an endorsement.